ADVFN Logo ADVFN

No pudimos encontrar ningún resultado para:
Asegúrate de que la ortografía sea correcta o intenta ampliar tu búsqueda.

Tendencias Ahora

Listas Principales

Parece que no has iniciado sesión.
Haz clic en el botón de abajo para iniciar sesión y ver tu historial reciente.

Hot Features

Registration Strip Icon for charts Regístrate para obtener gráficos en tiempo real, herramientas de análisis y precios.

NEXI NexImmune Inc

3.32
0.20 (6.41%)
03 May 2024 - Cerrado
Retrasado por 15 minutos
Nombre de la Acción Símbolo de la Acción Bolsa de Valores Tipo de Valor
NexImmune Inc NEXI NASDAQ Acción Común
  Variación del Día (ptos.) Variación del Día (%) Último Precio Hora
0.20 6.41% 3.32 23:00:06
Precio de Apertura Precio Mínimo Precio Máximo Precio de cierre Precio Anterior
3.13 3.10 3.4899 3.32 3.12
más cotizaciones de acciones »

Noticias Recientes

Fecha Hora Fuente Noticia
07/3/202412:20BWKonzernergebnis zum 31. Dezember 2023 genehmigt, starke..
07/3/202411:33BWApprobation des résultats financiers du groupe au 31..
07/3/202400:31BWApprovati i risultati finanziari di Gruppo al 31 dicembre..
07/3/202400:30BWGroup Financial Results as of December 31st 2023 Approved,..
06/2/202415:42GLOBENexImmune Announces Closing of $3.67 Million Registered..
06/2/202415:30EDGAR2Form DEFA14A - Additional definitive proxy soliciting..
05/2/202416:10EDGAR2Form 8-K - Current report
05/2/202415:34EDGAR2Form 424B5 - Prospectus [Rule 424(b)(5)]
02/2/202413:00GLOBENexImmune Announces $3.67 Million Registered Direct Offering..
02/2/202412:25EDGAR2Form 8-K - Current report
01/2/202408:17EDGAR2Form 8-K - Current report
19/1/202415:43EDGAR2Form 8-K - Current report
18/1/202415:43EDGAR2Form DEFA14A - Additional definitive proxy soliciting..
22/12/202315:01EDGAR2Form 8-K - Current report
01/12/202312:39EDGAR2Form 8-K - Current report
22/11/202316:40EDGAR2Form 144/A - Report of proposed sale of securities: [Amend]
22/11/202316:18EDGAR2Form 4 - Statement of changes in beneficial ownership of..
21/11/202315:39EDGAR2Form 144 - Report of proposed sale of securities
20/11/202316:19EDGAR2Form DEF 14A - Other definitive proxy statements
20/11/202316:01EDGAR2Form 8-K/A - Current report: [Amend]
17/11/202315:03EDGAR2Form 10-Q - Quarterly report [Sections 13 or 15(d)]
15/11/202315:17EDGAR2Form NT 10-Q - Notification of inability to timely file Form..
09/11/202316:47EDGAR2Form PRE 14A - Other preliminary proxy statements
09/11/202308:35BWFinanzergebnisse der Gruppe zum 30. September 2023..
09/11/202307:52BWLes résultats financiers du groupe au 30 septembre 2023 ont..
09/11/202300:30BWApprovati I Risultati Finanziari Di Gruppo Al 30 Settembre..
02/11/202316:12EDGAR2Form 8-K - Current report
02/11/202315:33EDGAR2Form 8-K - Current report
24/10/202307:00GLOBENexImmune, Yale, and JDRF Extend Research Partnership for..
19/10/202307:00GLOBENexImmune Announces Presentations at The Society for..
18/10/202315:15EDGAR2Form 8-K - Current report
18/10/202310:30GLOBENexImmune Announces 1-for-25 Reverse Stock Split
25/9/202315:42EDGAR2Form DEF 14A - Other definitive proxy statements
15/9/202315:06EDGAR2Form 8-K - Current report
13/9/202316:14EDGAR2Form PRE 14A - Other preliminary proxy statements
08/9/202318:23EDGAR2Form 3 - Initial statement of beneficial ownership of..
31/8/202316:11EDGAR2Form 8-K - Current report
31/8/202315:45GLOBENexImmune Announces Workforce Reduction to Enable Continued..
10/8/202315:15EDGAR2Form 10-Q - Quarterly report [Sections 13 or 15(d)]
10/8/202315:06EDGAR2Form 8-K - Current report
10/8/202315:01GLOBENexImmune Reports Second Quarter 2023 Financial Results and..
01/8/202317:21BWFinanzergebnisse der Gruppe zum 30. Juni 2023 bestätigen..
01/8/202300:23BWGroup Financial Results as of June 30th 2023, Approved Solid..
07/7/202315:24EDGAR2Form 4 - Statement of changes in beneficial ownership of..
07/7/202315:21EDGAR2Form 4 - Statement of changes in beneficial ownership of..
07/7/202315:17EDGAR2Form 4 - Statement of changes in beneficial ownership of..
07/7/202315:16EDGAR2Form 4 - Statement of changes in beneficial ownership of..
05/6/202307:01GLOBENexImmune Presents Initial Positive Data from the NEXI-001..
22/5/202315:01GLOBENexImmune Announces Poster Presentation at the 2023 FOCIS..
15/5/202315:01GLOBENexImmune Reports First Quarter 2023 Financial Results and..

Su Consulta Reciente

Delayed Upgrade Clock